| CD155 Expression in Acute Myeloid Leukemia (NCT06369662) | Assiut University | 2022-07-01 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (NCT05005299) | Melbourne Health | 2022-06-08 |
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy (NCT05154474) | Weprom | 2022-06-01 |
| A Long-term Follow-up Study of Patients Who Received VOR33 (NCT05309733) | Vor Biopharma | 2022-04-15 |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (NCT04988555) | Sumitomo Pharma America, Inc. | 2022-02-28 |
| A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (NCT05218902) | Bristol-Myers Squibb | 2022-02-25 |
| Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse (NCT05270200) | Zhujiang Hospital | 2022-02-01 |
| A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT05168202) | Bristol-Myers Squibb | 2022-01-19 |
| Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML (NCT05305859) | The First Affiliated Hospital of Xiamen University | 2022-01-12 |
| Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05008575) | Xinqiao Hospital of Chongqing | 2021-12-23 |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS (NCT04849910) | Vor Biopharma | 2021-12-16 |
| Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (NCT04951778) | Celgene | 2021-12-02 |
| A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (NCT04887857) | Celgene | 2021-12-01 |
| Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05016063) | Xinqiao Hospital of Chongqing | 2021-09-01 |
| Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML) (NCT04920188) | UNC Lineberger Comprehensive Cancer Center | 2021-05-28 |
| A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy (NCT04824924) | Shanghai Jiao Tong University School of Medicine | 2021-03-01 |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old (NCT04687761) | PETHEMA Foundation | 2020-11-04 |
| Acute Myeloid Leukemia Real World Treatment Patterns (NCT04230564) | Pfizer | 2020-10-31 |
| Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors (NCT06785077) | European Institute of Oncology | 2020-10-02 |
| ObServatory Children Acute RElated Therapy Leukemia (NCT04450784) | University Hospital, Bordeaux | 2020-09-01 |
| IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT (NCT04522895) | Heinrich-Heine University, Duesseldorf | 2020-08-27 |
| A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia (NCT04336982) | Celgene | 2020-08-05 |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia (NCT04209725) | SCRI Development Innovations, LLC | 2020-06-03 |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide (NCT04361058) | SCRI Development Innovations, LLC | 2020-04-13 |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World (NCT04337138) | Pfizer | 2020-04-07 |
| A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment (NCT04241549) | OncoVerity, Inc. | 2020-03-25 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592) | Celularity Incorporated | 2020-03-12 |
| Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (NCT04150887) | OncoVerity, Inc. | 2019-12-23 |
| Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients (NCT03690115) | Versailles Hospital | 2019-12-02 |
| Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia (NCT04272125) | Chongqing Precision Biotech Co., Ltd | 2019-12-01 |
| An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies (NCT04052126) | Centre Leon Berard | 2019-11-28 |
| Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (NCT03926624) | Delta-Fly Pharma, Inc. | 2019-11-22 |
| HDM201 Added to CT in R/R or Newly Diagnosed AML (NCT03760445) | Novartis Pharmaceuticals | 2019-11-15 |
| Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia (NCT04133220) | Assistance Publique - Hôpitaux de Paris | 2019-10-01 |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy (NCT04090736) | PETHEMA Foundation | 2019-09-24 |
| Oral Health Condition and Quality of Life in Children With Leukemia (NCT04968860) | Paulo Sergio da Silva Santos | 2019-09-01 |
| CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia (NCT04265963) | Chongqing Precision Biotech Co., Ltd | 2019-09-01 |
| A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (NCT04023526) | OncoVerity, Inc. | 2019-07-29 |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems (NCT03814005) | Takeda | 2019-07-10 |
| Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival (NCT03549351) | University Hospital Heidelberg | 2019-06-01 |
| A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT03915379) | Janssen Research & Development, LLC | 2019-03-28 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03850574) | Aptose Biosciences Inc. | 2019-03-11 |
| Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients (NCT03823352) | Golden Biotechnology Corporation | 2019-02-20 |
| Cardiovascular Function in Acute Leukemia (NCT03760237) | Abramson Cancer Center at Penn Medicine | 2018-12-10 |
| Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity (NCT03796533) | Hospices Civils de Lyon | 2018-12-10 |
| A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients (NCT03720366) | Celgene | 2018-10-04 |
| Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT (NCT03793517) | Peking University People's Hospital | 2018-09-01 |
| Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes (NCT03235973) | Institut Paoli-Calmettes | 2018-04-28 |
| A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (NCT03416179) | Pfizer | 2018-04-20 |
| Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) (NCT03315039) | Moleculin Biotech, Inc. | 2018-03-28 |
| CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML） (NCT03556982) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2018-03-01 |
| Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain (NCT03435341) | Celgene | 2018-02-28 |
| NLA101 in Adults Receiving High Dose Chemotherapy for AML (NCT03301597) | Nohla Therapeutics, Inc. | 2018-01-24 |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (NCT03268954) | Takeda | 2017-11-28 |
| A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy (NCT03298516) | Genentech, Inc. | 2017-11-15 |
| Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg® (NCT03287128) | Versailles Hospital | 2017-11-01 |
| Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia (NCT03335267) | Weill Medical College of Cornell University | 2017-10-19 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (NCT03066648) | Novartis Pharmaceuticals | 2017-07-06 |
| Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (NCT03173248) | Institut de Recherches Internationales Servier | 2017-06-26 |
| BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) (NCT03127735) | Bayer | 2017-06-14 |
| B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) (NCT02493829) | King's College London | 2017-05-01 |
| DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) (NCT03110354) | Daiichi Sankyo | 2017-04-05 |
| Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy (NCT02856464) | King's College Hospital NHS Trust | 2016-12-21 |
| Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation (NCT02984995) | Daiichi Sankyo Co., Ltd. | 2016-12-08 |
| King's Invasive Aspergillosis Study II (NCT02875743) | King's College Hospital NHS Trust | 2016-12-07 |
| A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (NCT03030612) | OncoVerity, Inc. | 2016-12-01 |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes (NCT02848001) | Celgene | 2016-11-14 |
| A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (NCT02527174) | University of Alberta | 2016-11-01 |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes (NCT02841540) | Hemavant Sciences GmbH | 2016-10-06 |
| A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms (NCT02842229) | Celgene | 2016-07-20 |
| A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) (NCT02781467) | Celularity Incorporated | 2016-07-11 |
| A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) (NCT02632721) | Boehringer Ingelheim | 2016-06-16 |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) (NCT02775903) | Celgene | 2016-06-03 |
| A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy (NCT02677922) | Celgene | 2016-06-03 |
| Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT02715011) | Janssen Research & Development, LLC | 2016-06-01 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (NCT02665065) | Actinium Pharmaceuticals | 2016-06-01 |
| PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients (NCT02928523) | MaaT Pharma | 2016-06-01 |
| A Study of Pevonedistat in Adult East Asian Participants (NCT02782468) | Millennium Pharmaceuticals, Inc. | 2016-05-16 |
| An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) (NCT02610777) | Millennium Pharmaceuticals, Inc. | 2016-04-14 |
| Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias (NCT02759822) | Leonardo Javier Arcuri | 2016-04-01 |
| Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia (NCT02682732) | Hamilton Health Sciences Corporation | 2016-04-01 |
| Prophylactic Application of Donor-derived TCM After Allogeneic HSCT (NCT02758223) | Wuerzburg University Hospital | 2016-04-01 |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy (NCT02670044) | Hoffmann-La Roche | 2016-03-09 |
| A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) (NCT02641002) | Celgene | 2016-03-01 |
| A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT02545283) | Hoffmann-La Roche | 2015-12-30 |
| Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML (NCT02485353) | Hamid Sayar | 2015-10-20 |
| A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. (NCT02450877) | Celgene | 2015-08-12 |
| An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy (NCT02472145) | Janssen Research & Development, LLC | 2015-08-04 |
| ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia (NCT02619071) | Institut Paoli-Calmettes | 2015-08-01 |
| Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT (NCT02472691) | Heinrich-Heine University, Duesseldorf | 2015-05-01 |
| SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction (NCT02348489) | Astex Pharmaceuticals, Inc. | 2015-03-19 |
| Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML (NCT02427919) | Seoul St. Mary's Hospital | 2015-03-01 |
| Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML (NCT02306291) | GlycoMimetics Incorporated | 2015-03-01 |
| A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome (NCT02328950) | Fujian Medical University | 2014-12-01 |
| Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia (NCT02345915) | Institut Paoli-Calmettes | 2014-11-01 |
| Phase I, Dose Escalation Study of Decitabine (NCT02264873) | University of Florida | 2014-10-01 |
| Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT01898793) | Washington University School of Medicine | 2014-08-11 |
| Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation (NCT02337595) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2014-08-01 |
| Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (NCT02117115) | Washington University School of Medicine | 2014-06-01 |
| Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML) (NCT02140606) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2014-05-01 |